Novo nordisk a/s: mim8 phase 1 & 2 data demonstrates potential as once monthly treatment for people with haemophilia a

N o thromboembolic events or related serious adverse events reported over 12-week observation period in frontier1 study. 1

NVO Ratings Summary

NVO Quant Ranking